Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain Tumor
- Sponsor
- Universitas Sumatera Utara
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- Value of Procalcitonin
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance
Detailed Description
This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria. Inclusion criteria: 1. Willing to be a sample 2. Complete medical records 3. Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor Exclusion criteria: 1. The patient's age is over 70 years 2. Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others 3. Patients with a history of brain tumor surgery or previous brain tumor treatment Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically. Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.
Investigators
Ridha Dharmajaya
Prof. Dr.
Universitas Sumatera Utara
Eligibility Criteria
Inclusion Criteria
- •Willing to be a sample
- •Complete medical records
- •Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor
Exclusion Criteria
- •The patient's age is over 70 years
- •Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others
- •Patients with a history of brain tumor surgery or previous brain tumor treatment
Outcomes
Primary Outcomes
Value of Procalcitonin
Time Frame: February-April 2020
Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Value of C-Reactive Protein
Time Frame: April- June 2020
Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Value of Neutrophyl to Lymphocyte Ratio (NLR)
Time Frame: June- August 2020
Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group)
Secondary Outcomes
- Demographic of samples(August- October 2020)